Nursing patients with neurological problems

2009 ◽  
pp. 435-484
Keyword(s):  
Multiple Sclerosis ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Physical Examination ◽  
Transient Ischaemic Attack ◽  
Diagnostic Tests ◽  
Degenerative Diseases ◽  
Nursing Assessment ◽  
Ischaemic Attack ◽  
Neurological Conditions

Nursing assessment of patients with neurological problems 436 Physical examination 438 Diagnostic tests 442 Neurological nursing problems 446 Epilepsy/seizure 448 Paralysis 450 Meningitis 452 Encephalitis 454 Chronic neurological conditions 456 Multiple sclerosis 458 Parkinson’s disease 460 Degenerative diseases 462 Stroke and transient ischaemic attack (TIA): overview ...

Nutrition in neurological conditions

2020 ◽  
pp. 781-794
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Motor Neurone ◽  
Motor Neurone Disease ◽  
Neurological Conditions

Multiple sclerosis, Motor neurone disease, Parkinson’s disease, Alzheimer’s disease, Ketogenic therapy for epilepsy

Degenerative Diseases (Multiple Sclerosis, Parkinson’s Disease)

Neuro-Urology ◽  
2018 ◽  
pp. 55-79 ◽  
Author(s):  
Petros Georgopoulos ◽  
Konstantinos-Vaios Mytilekas ◽  
Apostolos Apostolidis
Keyword(s):  
Multiple Sclerosis ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Degenerative Diseases

Polypharmacy in chronic neurological diseases: Multiple sclerosis, dementia and Parkinson’s disease

2021 ◽  
Vol 27 ◽  
Author(s):  
Niklas Frahm ◽  
Michael Hecker ◽  
Uwe Zettl
Keyword(s):  
Multiple Sclerosis ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurological Diseases ◽  
Severe Disease ◽  
Inappropriate Medication ◽  
Medication Management ◽  
Chronically Ill ◽  
Symptom Profile ◽  
Quantitative Definition

: Polypharmacy is an important aspect of medication management and particularly affects elderly and chronically ill people. Patients with dementia, Parkinson’s disease (PD) or multiple sclerosis (MS) are at high risk for multimedication due to their complex symptomatology. Our aim was to provide an overview of different definitions of polypharmacy and to present the current state of research on polypharmacy in patients with dementia, PD or MS. The most common definition of polypharmacy in the literature is the concomitant use of ≥5 medications (quantitative definition approach). Polypharmacy rates of up to >50% have been reported for patients with dementia, PD or MS, although MS patients are on average significantly younger than those with dementia or PD. The main predictor of polypharmacy is the complex symptom profile of these neurological disorders. Potentially inappropriate medication (PIM), drug-drug interactions, poor treatment adherence, severe disease course, cognitive impairment, hospitalisation, poor quality of life, frailty and mortality have been associated with polypharmacy in patients with dementia, PD or MS. For patients with polypharmacy, either the avoidance of PIM (selective deprescribing) or the substitution of PIM with more suitable drugs (appropriate polypharmacy) is recommended to achieve a more effective therapeutic management.

Sign in / Sign up

Export Citation Format

Share Document